Blood test to predict immunotherapy response in lung cancer and melanoma
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung cancer (NSCLC) or advanced melanoma that can't be removed with surgery.
- You are about to start treatment with an immunotherapy drug (like a PD-1 or PD-L1 inhibitor), alone or with other cancer treatments.
- You have not had immunotherapy before.
- You have at least one tumor that can be measured on a CT scan.
- You are generally well enough to be up and about (ECOG score 0–2), and your doctor expects you to live more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a simple blood test to see if it can predict how well immunotherapy will work for people with advanced cancer. It's for those newly diagnosed with certain cancers and about to start immunotherapy as their first treatment.
This trial is looking at a blood test to predict how well combined immunotherapy and chemotherapy will work in people with advanced lung cancer. It uses a new marker called ETASTs to help guide treatment decisions.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This trial is testing a simple blood test (liquid biopsy) to track how well melanoma responds to immunotherapy. It might help doctors decide if treatment is working or needs to be changed.
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.